Neurotone AI

AI-powered auditory rehabilitation platforms for hearing professionals

Website: https://www.neurotone.com/

Who Is Behind the Company

Rick Carlson (CEO) and Dr. Miles Aaron (COO) lead the firm, with Carlson's tenure beginning in March 2022 [Clay.earth / LinkedIn, 2026]. The product development of Tinnitus Pro involved recognized clinical advisors, including Dr. Robert Sweetow and Dr. Nancy Tye-Murray [The Hearing Review, 2024].

Data Accuracy: YELLOW -- Key executive roles and product launches are cited in trade press, but foundational corporate details lack independent corroboration.

Inside the Company

Neurotone AI operates as a specialized software provider in the audiology space, with its public identity built around the acquisition and modernization of a long-standing clinical tool. The company's primary asset is the LACE (Listening and Communication Enhancement) auditory training program [The Audiology Place, 2026]. Neurotone AI's recent corporate activity centers on integrating AI into this established platform and expanding into adjacent therapeutic areas, most notably with the launch of a digital tinnitus treatment product [PRWeb, Oct 2024].

Key leadership includes CEO and co-founder Rick Carlson and co-founder and COO Dr. Miles Aaron [Clay.earth / LinkedIn, 2026] [Hearing Health & Technology Matters, 2025]. The company has established affiliations with prominent clinical advisors, including Dr. Nancy Tye-Murray, PhD, and collaborated with specialists like Dr. Robert Sweetow and Dr. Jennifer Henderson Sabes on product development [The Hearing Review, 2024] [LinkedIn, 2026]. A significant reported milestone is the company's acquisition of Amptify, another digital auditory training platform, in 2026 [The Hearing Review, 2026].

Public milestones are primarily product-focused: the launch of Tinnitus Pro in October 2024 and the rebranding of its core offering to Lace AI Pro following a partnership with the program's original creators in early 2024 [PRWeb, Oct 2024] [Neurotone support, 2024]. The business model targets hearing care professionals directly, selling lifetime software licenses [Perplexity Sonar, 2024].

Data Accuracy: YELLOW -- Key executive roles and product launches are cited in trade press, but foundational corporate details lack independent corroboration.

Under the Hood

Neurotone AI's product strategy centers on a suite of B2B software platforms designed to serve hearing care professionals. The company's wedge is a clinical one, offering tools that aim to improve patient outcomes through personalized auditory training and therapy. The product line is built on a legacy of clinical validation, with its core LACE technology supported by more than 80 peer-reviewed publications and over 10 clinical trials [The Audiology Place, 2026].

Two primary products have been publicly launched. The first is Lace AI Pro, an evolution of the established LACE auditory training software. According to the company, this version was developed in early 2024 through a collaboration with the program's original creators [Neurotone support, 2024]. The second, and more recent, launch is Tinnitus Pro, announced in October 2024 [PRWeb, Oct 2024]. This product integrates sound therapy, cognitive behavioral therapy (CBT) tools, and clinician monitoring into a single digital application. Both products are sold via lifetime licenses to hearing professionals, with Tinnitus Pro cited at a $499 price point for patient licenses [Perplexity Sonar, 2024].

Data Accuracy: YELLOW -- Product details and pricing are sourced from company support pages and a single press release; the clinical research backing for LACE is well-documented in trade publications.

Market Research

Metric Value
Global Hearing Aid Market 2023 $10.5B
Projected CAGR 2024-2030 6%
People with hearing loss 2023 1.5 Billion
Projected with hearing loss 2050 2.5 Billion

Data Accuracy: YELLOW -- Market sizing figures are from third-party global health and industry reports, not company-specific estimates.

Competition and Substitutes

Neurotone AI operates in a niche where competition is defined by a fragmented ecosystem of point solutions, adjacent services, and the status quo of manual clinical practice. The competitive map segments into three layers: incumbent software tools, adjacent digital health substitutes, and the manual standard of care.

Neurotone AI's defensible edge rests on two pillars: proprietary clinical evidence and the integrated clinician portal. The claim that the LACE methodology is supported by over 80 peer-reviewed publications and 10+ clinical trials [The Audiology Place, 2026] creates a barrier to entry. By selling lifetime licenses to hearing care professionals [Perplexity Sonar, 2024] and providing tools for monitoring patient progress, the company embeds itself into the clinical workflow.

Data Accuracy: YELLOW -- Competitive positioning is inferred from product claims and market structure; no direct competitor data is publicly available for corroboration.

Opportunity

The prize for Neurotone AI is the transformation of the hearing care clinic from a hardware-centric sales channel into a high-retention, software-enabled service hub, capturing recurring value from the estimated 1.5 billion people globally with hearing loss [WHO, 2023]. The headline opportunity is to become the default clinical operating system for auditory rehabilitation. The LACE program, the predecessor to Lace AI Pro, is supported by more than 80 peer-reviewed publications and over 10 clinical trials [The Audiology Place, 2026].

Data Accuracy: YELLOW -- Core product claims and team affiliations are cited from trade press and company materials, but key commercial metrics and partnership details are not publicly available.

Sources

Articles about Neurotone AI

Related companies

Topics

View on Startuply.vc